Nektar Therapeutics (NKTR)
- Sector
- Pharmaceuticals
- Last price
- $35.91
- As of
Kresmion compiles this page from NKTR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
NEKTAR THERAPEUTICS (NKTR): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-13.
See the full NKTR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NKTR on one page. Preview it with sample data, then open it live with a free account.
Preview the NKTR dossierActive events for NKTR
- mediumEarnings above estimates
Q3-2026: Beat consensus by 22.8%, EPS $-1.63 vs $-2.1108 estimate
- high13F: funds added
3 tracked funds increased NKTR this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 39.2%, EPS $-1.23 vs $-2.0243 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +99% to NKTR (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +86% to NKTR (2026Q2)
FREE, NO ACCOUNT
Every event on NKTR, as it fires
You are seeing 5 of 13 events recorded on NKTR since 2026-05-26.
The five above landed across 4 days. The other 8 were recorded on 2 other days. 7 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, NKTR
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on NKTR
NKTR against its peers
NKTR's operating margin of -253.7% ranks in the 24th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | NKTR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 55.2M USD | 451M USD | 23 | 19 |
| Gross margin | n/a | 73.3% | n/a | 11 |
| Operating margin | -253.7% | 5.6% | 24 | 18 |
| Net margin | -297.1% | 0.5% | 23 | 19 |
| Return on equity | -182.6% | -6.5% | 2 | 22 |
| P / E | n/a | 14.7x | n/a | 9 |
| 1 year | -39.6% | 11.1% | 18 | 24 |
Peers (25): AMPH, INVA, OCUL, OMER, GPCR, PAHC, PCRX, NUVB, ANRO, ANIP, SUPN, TRVI, HRMY, ESPR.D, COLL, ALMS, ACRS, XERS, BHC, OGN, TARS, AMLX, AVIR, ACB, LQDA. Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NKTR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in NKTR on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on NKTR in the last 180 days.
Upstream: SEC EDGAR filings for NKTR
Kresmion, "NEKTAR THERAPEUTICS (NKTR) institutional holdings and SEC filings", data as of 2026-11-13, https://kresmion.com/research/NKTR. Upstream data: SEC EDGAR filings for NKTR.
Link to this data (HTML):
<a href="https://kresmion.com/research/NKTR">NEKTAR THERAPEUTICS (NKTR) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow NKTR on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to NKTR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.